Loading Events

Past Events

Events Search and Views Navigation

Event Views Navigation

January 2021

NIH R43/44 and U43/44

January 5
|Recurring Event (See all)

One event on January 5, 2021 at 12:00 am

One event on April 5, 2021 at 12:00 am

Sponsor: National Institutes of Health
DUE DATES: (same every year)

  • Cycle 1: Jan 5
  • Cycle 2: April 5
  • Cycle 3: September 5

BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (R43/R44 – Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.

Find out more »

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

January 10
|Recurring Event (See all)

One event on January 10, 2021 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Date: July 12, 2020, January 10, 2021
Application Due Date: August 11, 2020, February 9, 2021
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »

SfN Global Connectome

January 11 - January 13

This coming January 11–13, join the world’s largest neuroscience community for SfN Global Connectome: A Virtual Event. This brand-new, cross-cutting digital neuroscience event is designed to facilitate scientific exchange across the globe and across the field, providing scientists at all career stages, of all disciplines, with opportunities to learn, collaborate, and connect. As a 2020 or 2021 SfN member, you will be eligible to submit a digital abstract at no cost and will receive a reduced registration fee. Join or renew for 2020 or 2021 to get the best rates and submit an abstract.

Find out more »

February 2021

NIH R21, R03

February 16
|Recurring Event (See all)

One event on February 16, 2021 at 12:00 am

One event on October 16, 2021 at 12:00 am

Sponsor: National Institute of Health 
DUE DATES: 

  • Cycle 3: October 16, 2020 by 5 PM of local organization time
  • Cycle 1: February 16, 2021 by 5 PM of local organization time
  • Cycle 2: June 16, 2021 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »

March 2021

AES Seed Grant Program 

March 24

Sponsor: American Epilepsy Society
Due Dates: March 24, 2021
Award: The AES Seed Grant Program provides support to established investigators to pursue new and innovative directions in epilepsy research, bring new research methods to their research programs, or begin new collaborations with other investigators in epilepsy or in different, complementary disciplines. Seed Grants may provide up to $20,000 for one year for direct costs only, and they may not be renewed.

Find out more »

April 2021

NIH R43/44 and U43/44

April 5
|Recurring Event (See all)

One event on January 5, 2021 at 12:00 am

One event on April 5, 2021 at 12:00 am

Sponsor: National Institutes of Health
DUE DATES: (same every year)

  • Cycle 1: Jan 5
  • Cycle 2: April 5
  • Cycle 3: September 5

BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (SBIR) (R43/R44 – Clinical Trial Not Allowed): The purpose of this funding opportunity announcement (FOA) is to support the development of novel tools and technologies through the Small Business Technology Transfer (STTR) program to advance the field of neuroscience research. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.

Find out more »

Brain Barriers Virtual Meeting

April 7 - April 9

The purpose of this Cold Spring Harbor meeting is to explore and encourage new conceptual approaches and to apply novel methods to the neuroprotective physiologies of BBB structures. Our goal is pair genetic model organism biological methods with recent insights in vertebrate BBB physiology and development. We hope to create cross fertilization between fields that rarely see each other and get people thinking about how model systems can help parse the regulatory networks necessary for parsimonious BBB function.

Find out more »

May 2021

Experimental Biology Virtual Conference

May 1

Our new virtual meeting will bring you the latest research in anatomy, biochemistry, molecular biology, investigative pathology, pharmacology and physiology through an environment that fosters interaction amongst global attendees. Your virtual experience will be filled with lectures, workshops, symposia, posters presentations, exhibits and the opportunity to make connections with global scientists.

Find out more »

The 3rd Annual Margaret Hackett Family Program (MHFP) Symposium

May 21

This symposium will introduce a variety of central nervous system (CNS) congenital anomalies and the challenges of their treatments. Specific congenital syndromes will be visited in detail to describe treatment approaches. In addition, models of care as well as future approaches will be discussed.

Find out more »

July 2021

ADDF-Harrington Scholar Program

July 30

Sponsor: Alzheimer’s Drug Discovery Foundation
LOI due date:  April 23rd, 2021, 5:00 PM EDT
Full Application due date: July 30th, 2021, 5:00 PM EDT
Award: Up to $600,000 over 2 years with dedicated support from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The ADDF-Harrington Scholar Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias.

Find out more »

Cycle 1: Alzheimer’s Drug Discovery Foundation

July 30
|Recurring Event (See all)

One event on December 3, 2021 at 12:00 am

LOI Due Dates:

  • Cycle 1: May 28, 2021
  • Cycle 2: October 1, 2021

Full Proposal Deadlines:

  • Cycle 1: July 30, 2021
  • Cycle 2: December 3, 2021

Drug Development Program
The goal of this RFP is to develop therapeutics for Alzheimer’s disease and related dementias. This RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. Average Award: Up to $600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. Average Award: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged.
Neuroimaging and CSF Biomarker Development Prgram
The aim of this RFP is to develop biomarkers for which there is a clear clinical need in Alzheimer’s disease and related dementias. Average award: Up to $600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Average awards: $50,000-$100,000 for epidemiological analyses, and u to $3,000,000 for clinical trials based on stage and scope of research.

Find out more »

August 2021

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

August 10
|Recurring Event (See all)

One event on February 9, 2022 at 12:00 am

Sponsor: National Institutes of Health (multiple Institutes)
LOI Due Dates: 30 days before deadline
Due Date: August 10, 2021, February 9, 2022
Award: Application budgets are not limited but must reflect the actual needs of the proposed project. Applicants should rarely exceed up to $500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II. The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories.

Find out more »

September 2021

IF Multidisciplinary Care Conference

September 14 - September 17

Not only the Conference on Integrated Care is organised in order to share interests and updates from the national researchers of the countries participating in the recently published IF Multidisciplinary Care report, but it will also cover different sessions on different topics relevant to IF Members such as urology, ageing, sexual health, and mental health.

Find out more »

HANDS Animal Model Webinar Series – Week 1: Congenital Genetic Animal Models

September 17 @ 12:00 pm - 1:15 pm

Date: Friday, September 17th
Time: 12:00 to 1:15 PM EDT

Speakers:

  • Engin Deniz (Yale University) – Applications of frog (Xenopus tropicalis) model of congenital hydrocephalus
  • June Goto (University of Cincinnati) – Mouse and rat models of neonatal hydrocephalus with mutations (Ccdc39 and L1cam)
  • Scott Emmert (University of Cincinatti) – Mouse and rat models of neonatal hydrocephalus with mutations (Ccdc39 and L1cam) using CRISPR/Cas9

Register Here!

Find out more »

PCORI Implementation Awards

September 28

Sponsor: Patient-Centered Outcomes Research Institute (PCORI)
LOI Due Date: September 28, 2021 at 5pm ET
Application Due Date: December, 2021 at 5pm ET

Awards:
Limited PCORI Funding Announcement: Implementation of PCORI-Funded Patient-Centered Outcomes Research Results: Up to $1.5 million in total direct costs for Standard Implementation Projects, up to $4.5 million in total direct costs for Phased Implementation Projects, up to $300,000 in total costs for Dissemination Projects.
Implementation of Effective Shared Decision Making Approaches in Practice Settings: $1.5 million
Implementation of Findings from PCORI’s Major Research Investments: Up to $2.5 million

Find out more »

October 2021

PCORI Engagement Awards

October 1

Sponsor: Patient-Centered Outcomes Research Institute (PCORI)
LOI Due Date: October 1, 2021 at 5pm ET
Application Due Date: January 10, 2022 at 5pm ET

Awards:
Capacity Building: Award total costs may not exceed $250,000 (Direct + Indirect Costs)
Dissemination Initiative: Award total costs may not exceed $250,000 (Direct + Indirect Costs)
Stakeholder Convening Support: Award total costs may not exceed $100,000 (Direct + Indirect Costs)

Find out more »

PCORI Research Awards

October 5

Sponsor: Patient-Centered Outcomes Research Institute (PCORI)
LOI Due Date: October 5, 2021 at 5pm ET
Application Due Date: January 11, 2022 at 5pm ET

Awards:
Phased Large Awards for Comparative Effectiveness Research: $22 million (Feasibility phase: $2 million; Full-scale study phase: $20 million)
Comparative Effectiveness of Multimodal Interventions to Prevent Osteoporotic Fractures: Up to $10 million
Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention: Up to $10 million
Healthy Aging: Optimizing Physical and Mental Functioning Across the Aging Continuum: Up to $5 million
Broad PCORI Funding Announcements: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; and Improving Healthcare Systems: up to $3 million (Small) – up to $5 million (Large) — Communication & Dissemination Research: up to $2 million
Improving Methods for Conducting Patient-Centered Outcomes Research: $750,000

You can register here Virtual Applicant Town Halls for these Funding Announcements

Find out more »

Comparative Effectiveness of Multimodal Interventions to Prevent Osteoporotic Fractures

October 5

Sponsor: Patient-Centered Outcomes Research Institute (PCORI)
LOI Due Date: October 5, 2021 at 5pm ET
Application Due Date: January 11, 2022 at 5pm ET
Award: Up to $10 million

Find out more »

HANDS Animal Model Webinar Series – Week 3: Large Animal Models

October 14 @ 2:00 pm - 3:15 pm

(note different day/time)

Date: Thursday, October 14th
Time: 2:00 to 3:15 PM EDT

Speakers:

  • Simon Malpas (University of Auckland) – Development of sheep models for measuring intracranial pressure, blood pressure, and sympathetic activity in conscious animals
  • Pat McAllister (Washington University in St. Louis) – Development of pig models for shunting and third ventriculostomy with choroid plexus cauterization (ETV-CPC)

Register Here!

Find out more »

NIH R21, R03

October 16
|Recurring Event (See all)

One event on February 16, 2021 at 12:00 am

One event on October 16, 2021 at 12:00 am

Sponsor: National Institute of Health 
DUE DATES: 

  • Cycle 3: October 16, 2020 by 5 PM of local organization time
  • Cycle 1: February 16, 2021 by 5 PM of local organization time
  • Cycle 2: June 16, 2021 by 5 PM of local organization time

Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia: 
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
The combined budget for direct costs for the two year project period may not exceed $200,000.
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)
The combined budget for direct costs for the two-year project period may not exceed $275,000.  No more than $200,000 may be requested in any single year.
Chronic Condition Self-Management in Children and Adolescents (R21 Clinical Trial Optional)
Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Find out more »
+ Export Events